Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome
- PMID: 23819992
- PMCID: PMC3979150
- DOI: 10.1186/ar4248
Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome
Abstract
Introduction: The aim of this study was to examine the association between functional polymorphisms in the pro-inflammatory P2X7 receptor and the Ro/La autoantibody response in primary Sjögren's syndrome (pSS).
Methods: Twelve functional P2RX7 polymorphisms were genotyped in 114 pSS patients fulfilling the Revised American-European Consensus Criteria for pSS, and 136 controls. Genotyping of the A1405G (rs2230912) polymorphism was performed on a replication cohort consisting of 281 pSS patients and 534 controls. P2X7 receptor function in lymphocytes and monocytes was assessed by measurement of ATP-induced ethidium+ uptake. Serum IL-18 levels were determined by ELISA.
Results: The minor allele of P2RX7 A1405G is a tag for a common haplotype associated with gain in receptor function, as assessed by ATP-induced ethidium+ uptake. A positive association between 1405G and anti-Ro±La seropositive pSS patients was observed in Cohort 1. Although not replicated in Cohort 2, there was a consistent, significant, negative epistatic interaction effect with HLA-DR3 in seropositive pSS patients from both cohorts, thereby implicating this gain of function variant in the pathogenesis of pSS. Serum IL-18 was elevated in seropositive pSS patients, but was not influenced by P2RX7 A1405G.
Conclusions: The P2RX7 1405G gain-of-function haplotype may be a risk factor for seropositive pSS in a subset of subjects who do not carry HLA risk alleles, but has no effect in subjects who do (epistasis). Potential mechanisms relate to autoantigen exposure and inflammatory cytokine expression. The observed elevation of IL-18 levels is consistent with P2X7 receptor activation in seropositive pSS patients. Collectively these findings implicate P2X7 receptor function in the pathogenesis of pSS.
Figures



Similar articles
-
HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS).Clin Exp Immunol. 1998 Feb;111(2):365-71. doi: 10.1046/j.1365-2249.1998.00504.x. Clin Exp Immunol. 1998. PMID: 9486405 Free PMC article.
-
Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome.Rheumatology (Oxford). 2008 Sep;47(9):1311-6. doi: 10.1093/rheumatology/ken246. Epub 2008 Jul 10. Rheumatology (Oxford). 2008. PMID: 18617551
-
Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome.Ann Rheum Dis. 2008 Jun;67(6):849-54. doi: 10.1136/ard.2007.075044. Epub 2007 Sep 18. Ann Rheum Dis. 2008. PMID: 17878210 Free PMC article.
-
The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome.Autoimmun Rev. 2011 Jan;10(3):123-5. doi: 10.1016/j.autrev.2010.09.001. Epub 2010 Sep 15. Autoimmun Rev. 2011. PMID: 20833272 Review.
-
[Pathogenesis and diagnosis of Sjögren's syndrome].Z Rheumatol. 2010 Feb;69(1):50-6. doi: 10.1007/s00393-009-0519-2. Z Rheumatol. 2010. PMID: 20012975 Review. German.
Cited by
-
Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells.Immunol Cell Biol. 2015 Jan;93(1):77-85. doi: 10.1038/icb.2014.69. Epub 2014 Aug 26. Immunol Cell Biol. 2015. PMID: 25155463
-
P2 Receptors as Therapeutic Targets in the Salivary Gland: From Physiology to Dysfunction.Front Pharmacol. 2020 Mar 13;11:222. doi: 10.3389/fphar.2020.00222. eCollection 2020. Front Pharmacol. 2020. PMID: 32231563 Free PMC article. Review.
-
Making Sense of Intracellular Nucleic Acid Sensing in Type I Interferon Activation in Sjögren's Syndrome.J Clin Med. 2021 Feb 2;10(3):532. doi: 10.3390/jcm10030532. J Clin Med. 2021. PMID: 33540529 Free PMC article. Review.
-
Alum, an aluminum-based adjuvant, induces Sjögren's syndrome-like disorder in mice.Clin Exp Rheumatol. 2014 Mar-Apr;32(2):251-5. Epub 2014 Apr 9. Clin Exp Rheumatol. 2014. PMID: 24739520 Free PMC article.
-
Purinergic Signaling in Oral Tissues.Int J Mol Sci. 2022 Jul 14;23(14):7790. doi: 10.3390/ijms23147790. Int J Mol Sci. 2022. PMID: 35887132 Free PMC article. Review.
References
-
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;15:554–558. doi: 10.1136/ard.61.6.554. - DOI - PMC - PubMed
-
- Rischmueller M, Lester S, Chen Z, Champion G, Van Den Berg R, Beer R, Coates T, McCluskey J, Gordon T. HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS) Clin Exp Immunol. 1998;15:365–371. doi: 10.1046/j.1365-2249.1998.00504.x. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous